@phdthesis{Subramanian2011,
  author    = {Subramanian, Narayan},
  title     = {Role of NaV1.9 in activity dependent axon growth in embryonic cultured motoneurons},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-57536},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2011},
  abstract  = {Spontaneous neural activity has been shown to regulate crucial events in neurite growth including axonal branching and path finding. In animal models of spinal muscular atrophy (SMA) cultured embryonic mouse motoneurons show distinct defect in axon elongation and neural activity. This defect is governed by abnormal clustering of Ca2+ channels in the axonal regions and the protruding growth cone area. The mechanisms that regulate the opening of calcium channels in developing motoneurons are not yet clear. The question was addressed by blocking neural activity in embryonic cultured motoneurons by pharmacological inhibition of voltage-gated sodium channels (VGSC) by saxitoxin (STX) and tetrodotoxin (TTX). Low dosages of STX resulted in significant reduction of axon growth and neural activity in cultured motoneurons. This pharmacological treatment did not affect survival of motoneurons in comparison to control motoneurons that was grown in the presence of survival neurotrophic factors BDNF and CNTF. It was also found that STX was 10 times more potent than TTX a common inhibitor of VGSC with a reduced activity on the TTX-insensitive sodium channels NaV1.5, NaV1.8 and NaV1.9. Reverse Transcriptase-PCR experiments revealed the presence of NaV1.9 as the likely candidate that begins to express from embryonic stage sixteen in the mouse spinal cord. Immunolabelling experiments showed that the channel is expressed in the axonal compartments and axonal growth cones in cultured motoneurons. Suppression of NaV1.9 in cultured motoneurons by lentivirus mediated short hairpin-RNA (shRNA) resulted in shorter axon length in comparison with uninfected and scrambled constructs. Further, embryonic motoneurons cultured from NaV1.9 knockout mice also showed a significant reduction in neural activity and axon growth. The findings of this work highlight the role of NaV1.9 as an important contender in regulating activity dependent axon growth in embryonic cultured motoneurons. NaV1.9 could therefore be considered as a prospective molecule that could play an important role in regulating axon growth in motoneuron disease models like spinal muscular atrophy (SMA).},
  subject      = {Axon},
  language  = {en}
}
@phdthesis{Graulich2011,
  author    = {Graulich, Michael},
  title     = {Spinale Effekte von TNF-α am Modell des tumorinduzierten Knochenschmerzes der Maus},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-54439},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2011},
  abstract  = {Am Modell des tumorinduzierten Schmerzes der Maus wurden sowohl das Schmerzverhalten der Tiere als auch spezifische morphologische Ver{\"a}nderungen im Hinterhorn des R{\"u}ckenmarks (Aktivierung von Astrozyten) und im tumorbefallenen Knochen analysiert. Durch Analyse von M{\"a}usen mit Defizienz f{\"u}r TNF-Rezeptor 1, TNF-Rezeptor 2 oder f{\"u}r beide Rezeptoren konnte die Rolle von TNF-α seiner Rezeptoren bei der Entstehung von tumorinduziertem Schmerz untersucht werden. Im Unterschied zu neuropathischen Schmerzmodellen konnte gezeigt werden, dass beide TNF-Rezeptoren ausgeschaltet werden m{\"u}ssen, um eine signifikante Schmerzreduktion zu erzielen. Die systemische Behandlung mit dem TNF-neutralisierenden Fusionsprotein Etanercept konnte die im genetischen Modell gezeigte Reduktion der mechanischen Allodynie teilweise, aber nicht vollst{\"a}ndig reproduzieren. Eine Hemmung der Mikrogliaaktivierung mittels Minocyclin erbrachte im Tumor-schmerzmodell keinen Effekt auf das Schmerzverhalten der Tiere. Die histologische Analyse der tumoraffizierten Knochen zeigte eine signifikante Zunahme der Osteoklastenaktivit{\"a}t in tumortragenden Tieren. Die Behandlung mit Minocyclin war ohne erkennbaren Effekt auf die Differenzierung und die Aktivit{\"a}t der Osteoklasten. Es ergaben sich jedoch Hinweise, dass TNF-α einen hemmenden Einfluss auf die Osteoklastenaktivit{\"a}t im Knochentumormodell hat, da sowohl in den TNFR-KO-Tieren als auch unter Gabe von Etanercept eine Steigerung der Osteoklastenaktivit{\"a}t nachgewiesen werden konnte. Die Ergebnisse dieser Arbeit zeigen, dass TNF-α eine wichtige Rolle, sowohl in der Entstehung, als auch in der Aufrechterhaltung von tumorinduziertem Schmerz spielt. Hier liegt der Ansatzpunkt f{\"u}r weitere Studien mit dem Ziel, eine spezifische Pharmakotherapie zu entwickeln mit wirksamer TNF-α Blockade auch bei Patienten mit Tumorschmerzen. Nach den Erkenntnissen dieser Arbeit mit Etanercept sollte ein spezielles Augenmerk auf die ZNS-G{\"a}ngigkeit dieser Substanzen gelegt werden und die Gefahr der M{\"o}glichkeit eines vermehrten Tumorwachstum bedacht werden.},
  subject      = {Neuralgie},
  language  = {de}
}
@article{FrerichsSirenFeuersteinetal.1992,
  author    = {Frerichs, K. and Sir{\`e}n, Anna-Leena and Feuerstein, G. and Hallenbeck, JM},
  title     = {The onset of postischemic hypoperfusion in rats is precipitous and may be controlled by local neurons},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-47980},
  year      = {1992},
  abstract  = {Background and Purpose: Reperfusion following transient global cerebral ischemia is characterized by an initial hyperemic phase, which precedes hypo perfusion. The pathogenesis of these flow derangements remains obscure. Our study investigates the dynamics of postischemic cerebral blood flow changes, with particular attention to the role of local neurons. Metho(Js: We assessed local cortical blood flow continuously by laser Doppler flowmetry to permit observation of any rapid flow changes after forebrain ischemia induced by four-vessel occlusion for 20 minutes in rats. To investigate the role of local cortical neurons in the regulation of any blood flow fluctuations, five rats received intracortical microinjections of a neurotoxin (10 p,g ibotenic acid in 1 p,1; 1.5-mm-depth parietal cortex) 24 hours before ischemia to induce selective and localized neuronal depletion in an area corresponding to the sampie volume of the laser Doppler probe (1 mm3 ). Local cerebral blood flow was measured within the injection site and at an adjacent control site. Results: Ischemia was followed by marked hyperemia (235 ±23\% of control, n =7), followed by secondary hypoperfusion (45±3\% of control, n=7). The transition from hyperemia to hypoperfusioo occurred not gradually but precipitously (maximal slope of flow decay: 66±6\%/min; n=7). In ibotenic acid-injected rats, hyperemia was preserved at the injection site, but the sudden decline of blood flow was abolished (maximal slope of flow decay: 5±3\%/min compared with 53±8\%/min at the control site; n=5, p<O.OOI) and 00 significant hypoperfusion de\eloped (103±20\% of control at 60 minutes). Conclusions: These data suggest that the rapid transition to cortical hypo perfusion after forebrain ischemia may be triggered locally by a neuronal mechanism but that this mechanism does not underlie the initial hyperemia.},
  subject      = {Gehirn},
  language  = {en}
}
@techreport{MagnusLinkerMeuthetal.2011,
  author    = {Magnus, Tim and Linker, Ralf A. and Meuth, Sven G. and Kleinschnitz, Christoph and Korn, Thomas},
  title     = {Report on the 2nd scientific meeting of the "Verein zur Foerderung des Wissenschaftlichen Nachwuchses in der Neurologie" (NEUROWIND e.V.) held in Motzen, Germany, Oct. 29'th - Oct. 31'st, 2010},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-68789},
  year      = {2011},
  abstract  = {Summary of the scientific contributions to the NEUROWIND meeting 2010: Contributions in the fields of neuroimmunology and neurodegeneration},
  subject      = {Wissenschaftlicher Nachwuchs},
  language  = {en}
}
@phdthesis{Schubert2011,
  author    = {Schubert, Andrea Julia},
  title     = {Vergleich der Ergebnisse von Karotis-Stenting und -TEA an der Universit{\"a}tsklinik W{\"u}rzburg},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-67130},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2011},
  abstract  = {Der Vergleich der Verfahren Karotisstenting und Karotis-TEA an der Universit{\"a}tsklinik W{\"u}rzburg zeigt, dass bei richtiger Indikationsstellung sowie ausreichender Erfahrung der Neuroradiologen, CAS eine ernstzunehmende Alternative zu CEA darstellt. Besonderes Augenmerk lag dabei auf periprozeduale Komplikationen sowie Langzeitergebnisse bez{\"u}glich Tod,Insult und Restenose.},
  subject      = {Carotis},
  language  = {de}
}
@article{HaarmannDeissProchaskaetal.2010,
  author    = {Haarmann, Axel and Deiss, Annika and Prochaska, Juergen and Foerch, Christian and Weksler, Babette and Romero, Ignacio and Couraud, Pierre-Olivier and Stoll, Guido and Rieckmann, Peter and Buttmann, Mathias},
  title     = {Evaluation of Soluble Junctional Adhesion Molecule-A as a Biomarker of Human Brain Endothelial Barrier Breakdown},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-68468},
  year      = {2010},
  abstract  = {Background: An inducible release of soluble junctional adhesion molecule-A (sJAM-A) under pro-inflammatory conditions was described in cultured non-CNS endothelial cells (EC) and increased sJAM-A serum levels were found to indicate inflammation in non-CNS vascular beds. Here we studied the regulation of JAM-A expression in cultured brain EC and evaluated sJAM-A as a serum biomarker of blood-brain barrier (BBB) function. Methodology/Principal Findings: As previously reported in non-CNS EC types, pro-inflammatory stimulation of primary or immortalized (hCMEC/D3) human brain microvascular EC (HBMEC) induced a redistribution of cell-bound JAM-A on the cell surface away from tight junctions, along with a dissociation from the cytoskeleton. This was paralleled by reduced immunocytochemical staining of occludin and zonula occludens-1 as well as by increased paracellular permeability for dextran 3000. Both a self-developed ELISA test and Western blot analysis detected a constitutive sJAM-A release by HBMEC into culture supernatants, which importantly was unaffected by pro-inflammatory or hypoxia/reoxygenation challenge. Accordingly, serum levels of sJAM-A were unaltered in 14 patients with clinically active multiple sclerosis compared to 45 stable patients and remained unchanged in 13 patients with acute ischemic non-small vessel stroke over time. Conclusion: Soluble JAM-A was not suited as a biomarker of BBB breakdown in our hands. The unexpected non-inducibility of sJAM-A release at the human BBB might contribute to a particular resistance of brain EC to inflammatory stimuli, protecting the CNS compartment.},
  subject      = {Biomarker},
  language  = {en}
}
@article{DoerckGoebelWeiseetal.2010,
  author    = {Doerck, Sebastian and Goebel, Kerstin and Weise, Gesa and Schneider-Hohendorf, Tilman and Reinhardt, Michael and Hauff, Peter and Schwab, Nicholas and Linker, Ralf and Maeurer, Mathias and Meuth, Sven G. and Wiendl, Heinz},
  title     = {Temporal Pattern of ICAM-I Mediated Regulatory T Cell Recruitment to Sites of Inflammation in Adoptive Transfer Model of Multiple Sclerosis},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-68565},
  year      = {2010},
  abstract  = {Migration of immune cells to the target organ plays a key role in autoimmune disorders like multiple sclerosis (MS). However, the exact underlying mechanisms of this active process during autoimmune lesion pathogenesis remain elusive. To test if pro-inflammatory and regulatory T cells migrate via a similar molecular mechanism, we analyzed the expression of different adhesion molecules, as well as the composition of infiltrating T cells in an in vivo model of MS, adoptive transfer experimental autoimmune encephalomyelitis in rats. We found that the upregulation of ICAM-I and VCAM-I parallels the development of clinical disease onset, but persists on elevated levels also in the phase of clinical remission. However, the composition of infiltrating T cells found in the developing versus resolving lesion phase changed over time, containing increased numbers of regulatory T cells (FoxP3) only in the phase of clinical remission. In order to test the relevance of the expression of cell adhesion molecules, animals were treated with purified antibodies to ICAM-I and VCAM-I either in the phase of active disease or in early remission. Treatment with a blocking ICAM-I antibody in the phase of disease progression led to a milder disease course. However, administration during early clinical remission aggravates clinical symptoms. Treatment with anti-VCAM-I at different timepoints had no significant effect on the disease course. In summary, our results indicate that adhesion molecules are not only important for capture and migration of pro-inflammatory T cells into the central nervous system, but also permit access of anti-inflammatory cells, such as regulatory T cells. Therefore it is likely to assume that intervention at the blood brain barrier is time dependent and could result in different therapeutic outcomes depending on the phase of CNS lesion development.},
  subject      = {Multiple Sklerose},
  language  = {en}
}
@article{KraftSchwarzMeijersetal.2010,
  author    = {Kraft, Peter and Schwarz, Tobias and Meijers, Joost C. M. and Stoll, Guido and Kleinschnitz, Christoph},
  title     = {Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) Deficient Mice Are Susceptible to Intracerebral Thrombosis and Ischemic Stroke},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-68519},
  year      = {2010},
  abstract  = {Background: Thrombus formation is a key step in the pathophysiology of acute ischemic stroke and results from the activation of the coagulation cascade. Thrombin plays a central role in this coagulation system and contributes to thrombus stability via activation of thrombin-activatable fibrinolysis inhibitor (TAFIa). TAFIa counteracts endogenous fibrinolysis at different stages and elevated TAFI levels are a risk factor for thrombotic events including ischemic stroke. Although substantial in vitro data on the influence of TAFI on the coagulation-fibrinolysis-system exist, investigations on the consequences of TAFI inhibition in animal models of cerebral ischemia are still lacking. In the present study we analyzed stroke development and post stroke functional outcome in TAFI-/- mice. Methodology/Principal Findings: TAFI-/- mice and wild-type controls were subjected to 60 min transient middle cerebral artery occlusion (tMCAO) using the intraluminal filament method. After 24 hours, functional outcome scores were assessed and infarct volumes weremeasured from 2,3,5-Triphenyltetrazoliumchloride (TTC)-stained brain slices. Hematoxylin and eosin (H\&E) staining was used to estimate the extent of neuronal cell damage. Thrombus formation within the infarcted brain areas was analyzed by immunoblot. Infarct volumes and functional outcomes did not significantly differ between TAFI-/- mice and controls (p.0.05). Histology revealed extensive ischemic neuronal damage regularly including the cortex and the basal ganglia in both groups. TAFI deficiency also had no influence on intracerebral fibrin(ogen) formation after tMCAO. Conclusion: Our study shows that TAFI does not play a major role for thrombus formation and neuronal degeneration after ischemic brain challenge.},
  subject      = {Thrombus},
  language  = {en}
}
@article{KraftBenzAustinatetal.2010,
  author    = {Kraft, Peter and Benz, Peter Michael and Austinat, Madeleine and Brede, Marc Elmar and Schuh, Kai and Walter, Ulrich and Stoll, Guido and Kleinschnitz, Christoph},
  title     = {Deficiency of Vasodilator-Stimulated Phosphoprotein (VASP) Increases Blood-Brain-Barrier Damage and Edema Formation after Ischemic Stroke in Mice},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-68522},
  year      = {2010},
  abstract  = {Background: Stroke-induced brain edema formation is a frequent cause of secondary infarct growth and deterioration of neurological function. The molecular mechanisms underlying edema formation after stroke are largely unknown. Vasodilator-stimulated phosphoprotein (VASP) is an important regulator of actin dynamics and stabilizes endothelial barriers through interaction with cell-cell contacts and focal adhesion sites. Hypoxia has been shown to foster vascular leakage by downregulation of VASP in vitro but the significance of VASP for regulating vascular permeability in the hypoxic brain in vivo awaits clarification. Methodology/Principal Findings: Focal cerebral ischemia was induced in Vasp2/2 mice and wild-type (WT) littermates by transient middle cerebral artery occlusion (tMCAO). Evan's Blue tracer was applied to visualize the extent of blood-brainbarrier (BBB) damage. Brain edema formation and infarct volumes were calculated from 2,3,5-triphenyltetrazolium chloride (TTC)-stained brain slices. Both mouse groups were carefully controlled for anatomical and physiological parameters relevant for edema formation and stroke outcome. BBB damage (p,0.05) and edema volumes (1.7 mm360.5 mm3 versus 0.8 mm360.4 mm3; p,0.0001) were significantly enhanced in Vasp2/2 mice compared to controls on day 1 after tMCAO. This was accompanied by a significant increase in infarct size (56.1 mm3617.3 mm3 versus 39.3 mm3610.7 mm3, respectively; p,0.01) and a non significant trend (p.0.05) towards worse neurological outcomes. Conclusion: Our study identifies VASP as critical regulator of BBB maintenance during acute ischemic stroke. Therapeutic modulation of VASP or VASP-dependent signalling pathways could become a novel strategy to combat excessive edema formation in ischemic brain damage.},
  subject      = {Vasodilatator-stimuliertes Phosphoprotein},
  language  = {en}
}
@article{KleinschnitzGrundWingleretal.2010,
  author    = {Kleinschnitz, Christoph and Grund, Henrike and Wingler, Kirstin and Armitage, Melanie E. and Jones, Emma and Mittal, Manish and Barit, David and Schwarz, Tobias and Geis, Christian and Kraft, Peter and Barthel, Konstanze and Schuhmann, Michael K. and Herrmann, Alexander M. and Meuth, Sven G. and Stoll, Guido and Meurer, Sabine and Schrewe, Anja and Becker, Lore and Gailus-Durner, Valerie and Fuchs, Helmut and Klopstock, Thomas and de Angelis, Martin Hrabe and Jandeleit-Dahm, Karin and Shah, Ajay M. and Weissmann, Norbert and Schmidt, Harald H. H. W.},
  title     = {Post-Stroke Inhibition of Induced NADPH Oxidase Type 4 Prevents Oxidative Stress and Neurodegeneration},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-68416},
  year      = {2010},
  abstract  = {Ischemic stroke is the second leading cause of death worldwide. Only one moderately effective therapy exists, albeit with contraindications that exclude 90\% of the patients. This medical need contrasts with a high failure rate of more than 1,000 pre-clinical drug candidates for stroke therapies. Thus, there is a need for translatable mechanisms of neuroprotection and more rigid thresholds of relevance in pre-clinical stroke models. One such candidate mechanism is oxidative stress. However, antioxidant approaches have failed in clinical trials, and the significant sources of oxidative stress in stroke are unknown. We here identify NADPH oxidase type 4 (NOX4) as a major source of oxidative stress and an effective therapeutic target in acute stroke. Upon ischemia, NOX4 was induced in human and mouse brain. Mice deficient in NOX4 (Nox42/2) of either sex, but not those deficient for NOX1 or NOX2, were largely protected from oxidative stress, blood-brain-barrier leakage, and neuronal apoptosis, after both transient and permanent cerebral ischemia. This effect was independent of age, as elderly mice were equally protected. Restoration of oxidative stress reversed the stroke-protective phenotype in Nox42/2 mice. Application of the only validated low-molecular-weight pharmacological NADPH oxidase inhibitor, VAS2870, several hours after ischemia was as protective as deleting NOX4. The extent of neuroprotection was exceptional, resulting in significantly improved long-term neurological functions and reduced mortality. NOX4 therefore represents a major source of oxidative stress and novel class of drug target for stroke therapy.},
  subject      = {Schlaganfall},
  language  = {en}
}
@phdthesis{Fackelmann2011,
  author    = {Fackelmann, Stefanie},
  title     = {Langzeitkorrelation evozierter Potentialparameter mit dem klinischen Verlauf bei Patienten mit Multipler Sklerose},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-64840},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2011},
  abstract  = {Evozierte Potenziale werden bereits als Hilfsmittel zur Diagnosestellung der Multiplen Sklerose herangezogen. Das Spektrum der Verl{\"a}ufe der Erkrankung ist sehr unterschiedlich. Ziel der Studie war es, zu pr{\"u}fen, ob visuell (VEP), somatosensibel (SEP) und Magnet- (MEP) evozierte Potentiale durch das Aufdecken klinisch noch stummer L{\"a}sionen eine prognostische Bedeutung haben. Es wurden 94 Patienten bei Erstvorstellung sowie zum 5-Jahres- und 10-Jahresverlaufszeitpunkt untersucht. Es wurde ein Zusammenhang von MEP- und SEP-Scores mit dem sp{\"a}teren Behinderungsgrad, gemessen in Form der EDSS nach f{\"u}nf und zehn jahren gefunden, sofern die elektrophysiologischen Untersuchungen in den ersten beiden Jahren nach Erstmanifestation klinischer Symptome durchgef{\"u}hrt worden waren (Gruppe 1, 44 Patienten). F{\"u}r Gruppe 2 (50 Patienten), deren Erstuntersuchung sp{\"a}ter im Verlauf stattgefunden hatte (im Mittel 9,6a) konnte keine prognostische Bedeutung gesehen werden. Die Durchf{\"u}hrung multimodaler evozierter Potenziale ist kann somit eine Hilfestellung zur fr{\"u}hzeitigen Therapieentscheidung geben.},
  subject      = {Multiple Sklerose},
  language  = {de}
}
@phdthesis{Ruschil2014,
  author    = {Ruschil, Christoph},
  title     = {Der Einfluss von Autoantik{\"o}rpern gegen Aquaporin 4 bei der Pathogenese der Neuromyelitis optica},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-105787},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2014},
  abstract  = {Neuromyelitis optica (NMO) ist eine schwerwiegende Autoimmunerkrankung des zentralen Nervensystems, deren pathogene Ursache in Zusammenhang mit Autoantik{\"o}rpern gegen Aquaporin 4 (AQP4) steht. In einem intrathekalen Passiv-Transfermodell der Ratte wurden die Auswirkungen von NMO-Immunglobulin (IgG) aus Plasmapheresematerial und rekombinanten Antik{\"o}rpern gegen AQP4 sowie der Effekt von additiver Applikation von humanem Komplement untersucht. NMO-IgG, rekombinante Antik{\"o}rper und modifizierte Antik{\"o}rper ohne F{\"a}higkeit zur Aktivierung der Komplementkaskade waren bei repetitiver Applikation in der Lage, auch ohne additives humanes Komplement NMO-{\"a}hnliche progrediente motorische Symptome zu induzieren. Durch Ko-Injektion von humanem Komplement konnte keine signifikante Exazerbation der Pathologie bewirkt werden. MRT-Studien zeigten lokale Schrankenst{\"o}rungen am Ort der h{\"o}chsten Antik{\"o}rperkonzentration. In histologischen Aufarbeitungen von R{\"u}ckenmarksschnitten zeigten sich lokale Deposition an humanem IgG, ein dazu korrelierender Verlust an AQP4 sowie eine dar{\"u}ber hinausgehende Reduktion des Glutamattransporters EAAT2, w{\"a}hrend GFAP-reaktive Astrozyten tendenziell hypertroph und vermehrt waren. Auch bei additiver Applikation von humanem Komplement wiesen die L{\"a}sionsareale im Gegensatz zu histopathologischen Befunden bei NMO-Patienten und anderen Tiermodellen nur eine geringe Ablagerung von aktivem Komplement und wenig Infiltration durch ED1-positive Makrophagen auf. Da in einem Kontrollexperiment mit intrazerebraler intraparenchymaler Applikation von NMO-IgG die beschriebene additive Zytotoxizit{\"a}t von humanem Komplement reproduziert werden konnte, erscheint die Verwendbarkeit des intrathkalen Modells zur Evaluation der Wirkung von humanem Komplement bei Autoimmunerkrankungen mit intraspinalen Zielepitopen nicht geeignet. Die Ergebnisse lassen sich als Komplement-unabh{\"a}ngige intrinsische Wirkungen von Antik{\"o}rpern gegen AQP4 deuten, die in einer Reduktion der Oberfl{\"a}chenexpresseion von AQP4 und EAAT2 resultieren und zu einer progredienten Myelopathie f{\"u}hren. Neben der bekannten Antik{\"o}rper-induzierten Komplement-abh{\"a}ngigen Zytotoxizit{\"a}t k{\"o}nnten diese Effekte einen bislang nicht beschriebenen zus{\"a}tzlichen Pathomechanismus bei der NMO darstellen.},
  subject      = {Autoantik{\"o}rper},
  language  = {de}
}
@article{HaeuserWalittFitzcharlesetal.2014,
  author    = {H{\"a}user, Winfried and Walitt, Brian and Fitzcharles, Mary-Ann and Sommer, Claudia},
  title     = {Review of pharmacological therapies in fibromyalgia syndrome},
  series = {Arthritis Research \& Therapy},
  volume    = {16},
  journal   = {Arthritis Research \& Therapy},
  number    = {201},
  issn      = {1465-9913},
  doi       = {10.1186/ar4441},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-121598},
  year      = {2014},
  abstract  = {This review addresses the current status of drug therapy for the management of fibromyalgia syndrome (FMS) and is based on interdisciplinary FMS management guidelines, meta-analyses of drug trial data, and observational studies. In the absence of a single gold-standard medication, patients are treated with a variety of drugs from different categories, often with limited evidence. Drug therapy is not mandatory for the management of FMS. Pregabalin, duloxetine, milnacipran, and amitriptyline are the current first-line prescribed agents but have had a mostly modest effect. With only a minority of patients expected to experience substantial benefit, most will discontinue therapy because of either a lack of efficacy or tolerability problems. Many drug treatments have undergone limited study and have had negative results. It is unlikely that these failed pilot trials will undergo future study. However, medications, though imperfect, will continue to be a component of treatment strategy for these patients. Both the potential for medication therapy to relieve symptoms and the potential to cause harm should be carefully considered in their administration.},
  language  = {en}
}
@article{WeiseStoll2012,
  author    = {Weise, Gesa and Stoll, Guido},
  title     = {Magnetic resonance imaging of blood brain/nerve barrier dysfunction and leukocyte infiltration: closely related or discordant?},
  series = {Frontiers in Neurology},
  volume    = {3},
  journal   = {Frontiers in Neurology},
  number    = {178},
  doi       = {10.3389/fneur.2012.00178},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-123359},
  year      = {2012},
  abstract  = {Unlike other organs the nervous system is secluded from the rest of the organism by the blood brain barrier (BBB) or blood nerve barrier (BNB) preventing passive influx of fluids from the circulation. Similarly, leukocyte entry to the nervous system is tightly controlled. Breakdown of these barriers and cellular inflammation are hallmarks of inflammatory as well as ischemic neurological diseases and thus represent potential therapeutic targets. The spatiotemporal relationship between BBB/BNB disruption and leukocyte infiltration has been a matter of debate. We here review contrast-enhanced magnetic resonance imaging (MRI) as a non-invasive tool to depict barrier dysfunction and its relation to macrophage infiltration in the central and peripheral nervous system under pathological conditions. Novel experimental contrast agents like Gadofluorine M (Gf) allow more sensitive assessment of BBB dysfunction than conventional Gadolinium (Gd)-DTPA enhanced MRI. In addition, Gf facilitates visualization of functional and transient alterations of the BBB remote from lesions. Cellular contrast agents such as superparamagnetic iron oxide particles (SPIO) and perfluorocarbons enable assessment of leukocyte (mainly macrophage) infiltration by MR technology. Combined use of these MR contrast agents disclosed that leukocytes can enter the nervous system independent from a disturbance of the BBB, and vice versa, a dysfunctional BBB/BNB by itself is not sufficient to attract inflammatory cells from the circulation. We will illustrate these basic imaging findings in animal models of multiple sclerosis, cerebral ischemia, and traumatic nerve injury and review corresponding findings in patients.},
  language  = {en}
}
@article{AblinFitzcharlesBuskilaetal.2013,
  author    = {Ablin, Jacob and Fitzcharles, Mary-Ann and Buskila, Dan and Shir, Yoram and Sommer, Claudia and H{\"a}user, Winfried},
  title     = {Treatment of Fibromyalgia Syndrome: Recommendations of Recent Evidence-Based Interdisciplinary Guidelines with Special Emphasis on Complementary and Alternative Therapies},
  series = {Evidence-Bayed Complementary and Alternative Medicine},
  journal   = {Evidence-Bayed Complementary and Alternative Medicine},
  issn      = {1741-427X},
  doi       = {10.1155/2013/485272},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-122235},
  pages     = {485272},
  year      = {2013},
  abstract  = {Objective. Current evidence indicates that there is no single ideal treatment for fibromyalgia syndrome (FMS). First choice treatment options remain debatable, especially concerning the importance of complementary and alternative medicine (CAM) treatments. Methods. Three evidence-based interdisciplinary guidelines on FMS in Canada, Germany, and Israel were compared for their first choice and CAM-recommendations. Results. All three guidelines emphasized a patient-tailored approach according to the key symptoms. Aerobic exercise, cognitive behavioral therapy, and multicomponent therapy were first choice treatments. The guidelines differed in the grade of recommendation for drug treatment. Anticonvulsants (gabapentin, pregabalin) and serotonin noradrenaline reuptake inhibitors (duloxetine, milnacipran) were strongly recommended by the Canadian and the Israeli guidelines. These drugs received only a weak recommendation by the German guideline. In consideration of CAM-treatments, acupuncture, hypnosis/guided imagery, and Tai Chi were recommended by the German and Israeli guidelines. The Canadian guidelines did not recommend any CAM therapy. Discussion. Recent evidence-based interdisciplinary guidelines concur on the importance of treatment tailored to the individual patient and further emphasize the need of self-management strategies (exercise, and psychological techniques).},
  language  = {en}
}
@article{HansenSeilerRumpfetal.2012,
  author    = {Hansen, Niels and Seiler, Carola and Rumpf, Julian and Kraft, Peter and Dlaske, Henry and Abele-Horn, Marianne and Muellges, Wolfgang},
  title     = {Human Tuberculous Meningitis Caused by \(Mycobacterium\) \(caprae\)},
  series = {Case Reports in Neurology},
  volume    = {4},
  journal   = {Case Reports in Neurology},
  number    = {1},
  doi       = {10.1159/000337299},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-123425},
  pages     = {54-60},
  year      = {2012},
  abstract  = {INTRODUCTION: Tuberculous meningitis (TM) causes substantial morbidity and mortality in humans. Human TM has been known to be induced by bacteria from the Mycobacterium tuberculosis complex (MTBC), such as M. tuberculosis and M. bovis. CASE PRESENTATION: We describe a case of meningitis treated with fosfomycin, which showed partial effectiveness in an 80-year-old patient. After a lethal myocardial infarction, M. caprae (MC) was identified in cerebrospinal fluid culture. This isolated acid-fast organism was first identified as MTBC by MTBC-specific PCR (16S rDNA-PCR). Furthermore, species-specific identification of the isolate was done by gyrB PCR-restriction fragment length polymorphism analysis of a part of gyrB DNA. Colony morphology of the isolated MC strain showed dysgonic growth on Lowenstein-Jensen medium. The strain was susceptible to pyrazinamide (PZA). CONCLUSION: This isolated strain was convincingly identified as MC according to the phenotypic and genotypic characteristics and PZA sensitivity. This is the first report of MC causing TM.},
  language  = {en}
}
@article{BoltzeKleinschnitzReymannetal.2012,
  author    = {Boltze, Johannes and Kleinschnitz, Christoph and Reymann, Klaus G. and Reiser, Georg and Wagner, Daniel-Christoph and Kranz, Alexander and Michalski, Dominik},
  title     = {Neurovascular pathophysiology in cerebral ischemia, dementia and the ageing brain - current trends in basic, translational and clinical research},
  series = {Experimental \& Translational Stroke Medicine},
  volume    = {4},
  journal   = {Experimental \& Translational Stroke Medicine},
  number    = {14},
  doi       = {doi:10.1186/2040-7378-4-14},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-126679},
  year      = {2012},
  abstract  = {The 7th International Symposium on Neuroprotection and Neurorepair was held from May 2nd to May 5th, 2012 in Potsdam, Germany. The symposium, which directly continues the successful Magdeburg meeting series, attracted over 330 colleagues from 29 countries to discuss recent findings and advances in the field. The focus of the 2012 symposium was widened from stroke and traumatic brain injury to neurodegenerative diseases, notably dementia, and more generally the ageing brain. Thereby, emphasis was given on neurovascular aspects of neurodegeneration and stroke including the blood-brain barrier, recent findings regarding the pathomechanism of Alzheimer's disease, and brain imaging approaches. In addition, neurobiochemical aspects of neuroprotection, the role of astrogliosis, the clinical progress of cell-based approaches as well as translational hurdles and opportunities were discussed in-depth. This review summarizes some of the most stimulating discussions and reports from the meeting.},
  language  = {en}
}
@article{KraftDeMeyerKleinschnitz2012,
  author    = {Kraft, Peter and De Meyer, Simon F. and Kleinschnitz, Christoph},
  title     = {Next-Generation Antithrombotics in Ischemic Stroke: Preclinical Perspective on 'Bleeding-Free Antithrombosis'},
  series = {Journal of Cerebral Blood Flow and Metabolism},
  volume    = {32},
  journal   = {Journal of Cerebral Blood Flow and Metabolism},
  number    = {10},
  doi       = {10.1038/jcbfm.2012.108},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-126538},
  pages     = {1831-1840},
  year      = {2012},
  abstract  = {The present antithrombotic drugs used to treat or prevent ischemic stroke have significant limitations: either they show only moderate efficacy (platelet inhibitors), or they significantly increase the risk for hemorrhages (thrombolytics, anticoagulants). Although most strokes are caused by thrombotic or embolic vessel occlusions, the pathophysiological role of platelets and coagulation is largely unclear. The introduction of novel transgenic mouse models and specific coagulation inhibitors facilitated a detailed analysis of molecular pathways mediating thrombus formation in models of acute ischemic stroke. Prevention of early platelet adhesion to the damaged vessel wall by blocking platelet surface receptors glycoprotein Ib alpha (GPIbα) or glycoprotein VI (GPVI) protects from stroke without provoking bleeding complications. In addition, downstream signaling of GPIbα and GPVI has a key role in platelet calcium homeostasis and activation. Finally, the intrinsic coagulation cascade, activated by coagulation factor XII (FXII), has only recently been identified as another important mediator of thrombosis in cerebrovascular disease, thereby disproving established concepts. This review summarizes the latest insights into the pathophysiology of thrombus formation in the ischemic brain. Potential clinical merits of novel platelet inhibitors and anticoagulants as powerful and safe tools to combat ischemic stroke are discussed.},
  language  = {en}
}
@article{KraftDrechslerSchuhmannetal.2015,
  author    = {Kraft, Peter and Drechsler, Christiane and Schuhmann, Michael K. and Gunreben, Ignaz and Kleinschnitz, Christoph},
  title     = {Characterization of Peripheral Immune Cell Subsets in Patients with Acute and Chronic Cerebrovascular Disease: A Case-Control Study},
  series = {International Journal of Molecular Science},
  volume    = {16},
  journal   = {International Journal of Molecular Science},
  number    = {10},
  doi       = {10.3390/ijms161025433},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-126319},
  pages     = {25433-25449},
  year      = {2015},
  abstract  = {Immune cells (IC) play a crucial role in murine stroke pathophysiology. However, data are limited on the role of these cells in ischemic stroke in humans. We therefore aimed to characterize and compare peripheral IC subsets in patients with acute ischemic stroke/transient ischemic attack (AIS/TIA), chronic cerebrovascular disease (CCD) and healthy volunteers (HV). We conducted a case-control study of patients with AIS/TIA (n = 116) or CCD (n = 117), and HV (n = 104) who were enrolled at the University Hospital W{\"u}rzburg from 2010 to 2013. We determined the expression and quantity of IC subsets in the three study groups and performed correlation analyses with demographic and clinical parameters. The quantity of several IC subsets differed between the AIS/TIA, CCD, and HV groups. Several clinical and demographic variables independently predicted the quantity of IC subsets in patients with AIS/TIA. No significant changes in the quantity of IC subsets occurred within the first three days after AIS/TIA. Overall, these findings strengthen the evidence for a pathophysiologic role of IC in human ischemic stroke and the potential use of IC-based biomarkers for the prediction of stroke risk. A comprehensive description of IC kinetics is crucial to enable the design of targeted treatment strategies.},
  language  = {en}
}
@article{FluriFleischerKleinschnitz2015,
  author    = {Fluri, Felix and Fleischer, Michael and Kleinschnitz, Christoph},
  title     = {Accidental Thrombolysis in a Stroke Patient Receiving Apixaban},
  series = {Cerebrovascular Diseases Extra},
  volume    = {5},
  journal   = {Cerebrovascular Diseases Extra},
  doi       = {10.1159/000375181},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-126326},
  pages     = {55-56},
  year      = {2015},
  abstract  = {No abstract available.},
  language  = {en}
}